Samstag, C. L. | Search bioRxiv

bioRxiv2026

Hepatic huntingtin loss drives an acute phase response and liver injury in multiple mouse models

Multiple therapeutic strategies are being developed to slow Huntingtons disease (HD) progression through targeted reduction of huntingtin (HTT) protein or mRNA. Despite HTTs discovery over 30 years ago, its cellular functions remain incompletely understood, and the long-term consequences of HTT-lowering therapies remain unclear. We previously demonstrated that hepatic HTT loss in mice disrupts hepatocyte zonation and metabolism. Here, we investigate the physiological consequences of hepatic Htt loss. Across multiple models of Htt loss--including ubiquitous and hepatocyte-specific genetic knockouts and a therapeutically relevant Htt-targeting siRNA--there was elevated expression of IL-6/STAT3-driven acute phase response genes. Single-nucleus RNA sequencing reveals a zonal pattern of hepatocyte stress, most highly upregulated in pericentral hepatocytes, and identifies a distinct pericentral cluster of stressed hepatocytes that was enriched [~]9.6-fold following Htt knockout. Histological examination reveals that Htt loss results in increased hepatic pathology, including hepatic intranuclear inclusions, apoptosis, and necrosis, as well as prevalence of granulomas. Transcriptomic analysis reveals significant upregulation of metallothionein genes following Htt loss, as confirmed by elevated plasma metallothionein-1 (MT1) levels in knockout mice. These findings underscore important safety considerations for HTT-lowering therapies and suggest candidate biomarkers for monitoring hepatic off-target effects in clinical trials.

molecular biology↗

bioRxiv2026

GBA1 deficiency differentially affects endolysosomal trafficking in neurons versus astrocytes

Mutations in the gene glucosidase, beta acid 1 (GBA1) are the strongest genetic risk factor for Parkinsons disease (PD) and are associated with faster disease progression. GBA1 is expressed in all cell types of the central nervous system, with some evidence supporting higher expression in glial cells than neurons. To elucidate possible specific functions in neurons versus glia, we differentiated human induced pluripotent stem cells (iPSCs) generated from an individual with PD heterozygous for the GBA1 pathogenic null variant IVS2+1 (GBA1IVS/+), homozygous GBA1 IVS2+1 isogenic to GBA1IVS/+ (GBA1IVS/IVS) and a healthy unaffected age-and sex-matched individual (GBA1+/+). GBA1 expression was reduced in GBA1IVS/+ and GBA1IVS/IVS neurons and astrocytes. Endolysosomal trafficking was significantly altered in GBA1-deficient neurons with enlarged early and recycling endosome and lysosome compartments in neurons but not in astrocytes. High molecular weight oligomerization of -synuclein and phosphorylated Ser129 -synuclein were present in GBA1IVS/+ and GBA1IVS/IVS neurons but not in GBA1+/+ neurons, or in GBA1-deficient or GBA1+/+ astrocytes. Transcriptomic analysis of GBA1-deficient neurons and astrocytes revealed cell-type specific profiles. GBA1 deficiency in neurons downregulated immune response and upregulated cholesterol synthesis pathways, while GBA1 deficiency in astrocytes downregulated genes associated with translation and upregulated genes involved in extracellular matrix biogenesis. Transcriptomic analysis also suggests that GBA1 deficiency induces neurotoxic reactivity in astrocytes. Together, these findings indicate that GBA1 deficiency has cell type-specific effects, with increased neuronal vulnerability to endolysosomal trafficking leading to -synucleinopathy while GBA1 deficiency in astrocytes leads to increased neurotoxic reactivity independent of endolysosomal trafficking and -synucleinopathy. HighlightsO_LIiPSC-derived neurons and astrocytes modeled GBA1 deficiency C_LIO_LIEndolysosomal trafficking defects occurred only in GBA1-deficient neurons C_LIO_LI-synuclein oligomers accumulated in GBA1-deficient neurons, not astrocytes C_LIO_LIAstrocyte GBA1 loss drove neurotoxic reactive gene signatures C_LIO_LIGBA1 deficiency causes cell-type specific pathology C_LI

neuroscience↗